ROMA II RELOAD multicenter study (General Hospital Umberto I, University of Rome, Rome, Italy) assessed the impact of an additional charge of statin in patients undergoing elective angioplasty. All patients received a rosuvastatin dose of 40 mg (GR) or atorvastatin 80 mg (GA) within 24 hours of the procedure. The primary endpoint of the study…
SORT OUT V: Comparison of drug-eluting stents: One with degradable polymer releasing biolimus and the other a permanent polymer sirolimus stent.
SORT OUT V randomized trial (Odense University Hospital, Denmark) compared Nobori stent, a drug-eluting stent with biodegradable polymer eluting biolimus, versus CYPHER a drug-eluting stent with permanent polymer in the real world. Danish researchers used a non-inferiority design, by means of a primary objective of the study, the combined rate of major cardiac events (cardiac…
EVOLUTION: Comparative study of non-inferiority of two sirolimus eluting stents: One with permanent polymer and the other with degradable polymer.
The EVOLUTION study, (Dr. Junbo Ge, Shanghai Institute, China), compared two sirolimus-eluting stents, one with permanent polymer (Cypher Select, Cordis Corporation, Miami Lakes, Florida, USA) and another with degradable polymer (Excel, JW Medical System Ltd, Weihai, China). A randomized (2:1) was used, open and non-inferiority, including 1923 patients in 30 centers in China (December 2008…
CIBELES: Xience V comparative study vs Cypher for the treatment of total chronic occlusions.
Spanish-Portuguese multicentre CIBELES study (Raul Moreno, Madrid, Spain) compared two drug-eluting stents – an everolimus (Xience V, Abbott Vascular, USA) and a sirolimus-releasing eluting stent (Cypher Select, Cordis Corporation, Miami Lakes, Florida, USA) in the context of total chronic coronary occlusions. With a non-inferiority design, the study randomized 208 patients (1:1), using as the primary…